Lipid Therapeutics Plans U.S. Ulcerative Colitis Trials With Lipid Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. Phase III studies could start in the next 12 months with Lipid Therapeutics’ purified formulation of phosphatidylcholine to reverse deficiencies in the gastrointestinal mucosal barrier in patients with ulcerative colitis.